Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The approval of the first Class III medical device, recombinant type I collagen, opens new growth avenues in the medical aesthetics sector [7] - The company is a leader in the recombinant collagen field in China, with strong brand and product capabilities, supported by a core technology platform and channel expansion [7] - The company has four additional recombinant collagen injection products under application, with the latest approval expected to catalyze growth [7] - Continuous innovation in research and development is expanding the application boundaries of technology, with recent patent grants enhancing the company's product offerings [7] - Financial forecasts indicate a robust growth trajectory, with projected net profits of 2.57 billion, 3.21 billion, and 4.05 billion yuan for 2025, 2026, and 2027 respectively, reflecting year-on-year growth rates of 24%, 25%, and 26% [7] Financial Summary - Total revenue is projected to grow from 5.54 billion yuan in 2024 to 11.62 billion yuan in 2027, with year-on-year growth rates of 57.17%, 28.60%, 27.20%, and 28.23% respectively [1][8] - The latest diluted EPS is expected to increase from 1.93 yuan in 2024 to 3.78 yuan in 2027, with corresponding P/E ratios decreasing from 19.47 to 9.92 [1][8] - The company maintains a low debt ratio of 18.58%, indicating strong financial health [6]

Group 1: Market Overview - On October 23, the Hong Kong stock market saw a net inflow of 5.345 billion HKD from northbound trading, with 4.77 billion HKD from Shanghai and 575 million HKD from Shenzhen [2] - The most bought stocks included China National Offshore Oil Corporation (00883), Pop Mart (09992), and Meituan-W (03690), while the most sold stocks were Hua Hong Semiconductor (01347), Innovent Biologics (01801), and Xiaomi Group-W (01810) [2] Group 2: Individual Stock Performance - Alibaba-W (09988) had a net inflow of 2.68 billion HKD, with total trading volume of 4.975 billion HKD [3] - Pop Mart (09992) recorded a net inflow of 5.38 billion HKD, with total trading volume of 4.666 billion HKD [3] - Semiconductor stocks showed divergence, with SMIC (00981) receiving a net inflow of 4.25 billion HKD, while Hua Hong Semiconductor (01347) faced a net outflow of 10.14 billion HKD [7] Group 3: Company-Specific News - China National Offshore Oil Corporation (00883) received a net inflow of 9.79 billion HKD, driven by rising international oil prices due to sanctions on Russian oil companies [6] - Pop Mart (09992) saw a net inflow of 7.93 billion HKD, with Morgan Stanley reporting a sales growth of 245% to 250% in Q3, exceeding expectations [6] - Meituan-W (03690) had a net inflow of 5.24 billion HKD, with strategic moves to enhance its overseas business [7] - SMIC (00981) is expected to benefit from increased demand for advanced wafer foundry services due to the growth of AI applications, leading to an upgrade in its rating and target price by Morgan Stanley [7] - Innovent Biologics (01801) and Xiaomi Group-W (01810) faced net outflows of 140 million HKD and 57.32 million HKD, respectively [8]

Macro Economic Group - The report emphasizes the return to the central theme of "economic construction," with a goal for per capita GDP to reach the level of moderately developed countries by 2035. The expected economic growth target during the 14th Five-Year Plan period is around 5% [4] - It highlights the dual focus on growth and security, acknowledging the complex domestic and international situation, and the need to enhance economic, technological, and national defense capabilities [4] - The report stresses the importance of technological self-reliance and maintaining a stable manufacturing sector as strategic priorities, aiming to build a modern industrial system [4] - Expanding domestic demand and facilitating a smooth domestic circulation are identified as long-term directions, with an emphasis on boosting consumption and effective investment [4] Industry Comprehensive Group - Multiple PCB industry chain companies reported accelerated growth in Q3 2025. For instance, Shengyi Technology achieved revenue of 12.7 billion yuan, a 32% year-on-year increase, and a net profit of 1.38 billion yuan, up 52% [6] - Ding Tai High-Tech, a producer of PCB production tools, reported Q3 revenue of 1.46 billion yuan, a 29% increase, with net profit rising 80% to 260 million yuan [6] - Dongwei Technology, which manufactures PCB plating equipment, saw Q3 revenue of 760 million yuan, a 31% increase, and a net profit of 80 million yuan, up 38% [6] - The report indicates that the demand for high-layer and HDI boards driven by AI is leading to increased capacity utilization, suggesting a positive outlook for the PCB industry [6] Advanced Manufacturing Group - DFD's main business includes high-performance inorganic fluorides and electronic chemicals. In Q3, it reported revenue of 2.4 billion yuan, a 5.18% increase, and a net profit of 26.72 million yuan, marking a return to profitability [9] - The price of lithium hexafluorophosphate reached 85,000 to 90,000 yuan per ton, with expectations for increased volume and price in Q4 due to rising demand in energy storage and electric vehicles [9] - The company plans to expand its battery production capacity significantly, aiming for 20 GWh by the end of the year and further increases to 120 GWh in subsequent years [9] Consumer Group - Juzhi Biotechnology made a significant breakthrough in the medical beauty sector by obtaining approval for its recombinant type I α1 collagen freeze-dried fibers, targeting the facial dermis and entering the promising collagen injection market [11][12] - The gaming industry received favorable policy support, with the National Press and Publication Administration issuing 166 new game licenses, indicating a stable supply-side environment for the industry [11] - The report suggests that companies with new licenses and enhanced product pipelines are well-positioned to capitalize on market opportunities as the industry gradually recovers [11]

Investment Rating - The report does not explicitly state an investment rating for Giant Biogene, but it highlights the company's strong market position and potential for growth in the medical aesthetics sector. Core Insights - Giant Biogene's "Recombinant Type I α1 Collagen Lyophilized Fiber" received Class III Medical Device Registration from NMPA on October 21, 2024, marking its entry into the medical aesthetics injectables market [1][7]. - The approved Type I collagen is distinct from the Type III collagen already marketed by Jinbo Bio, allowing for unique product positioning [2][8]. - The product utilizes a long amino acid sequence (753 amino acids) and achieves high purity (99.9%), which are critical for its bioactivity and safety [3][9]. - The company has established a significant first-mover advantage with six operational production lines, exceeding ten tons of annual capacity, which supports rapid commercialization [4][10]. - The regulatory landscape for collagen injectables is stringent, with only 11 products approved from 7 companies, positioning Giant Biogene favorably against competitors [5][11]. - The approval paves the way for additional product applications, with two other medical aesthetic products currently under review [12]. Summary by Sections Product Approval - Giant Biogene's recombinant collagen product is approved for facial dermal tissue filling to correct dynamic wrinkles, showcasing the company's capabilities from R&D to commercial production [1][7]. Technical Differentiation - The company's collagen product is molecularly distinct from existing products, utilizing a specific amino acid sequence that does not form a triple-helical structure, reflecting advanced regulatory understanding [2][8]. - The proprietary molecular library of over 50 recombinant collagen molecules provides a solid foundation for future product iterations [3][9]. Production Capacity - The company has built a high-purity production line since 2021 and expanded its capacity to six lines, ensuring a robust supply chain for commercialization [4][10]. Market Landscape - The high regulatory barriers in the collagen injectables market favor established players like Giant Biogene, which benefits from superior biocompatibility and lower production costs compared to traditional animal-derived collagen [5][11]. Future Prospects - The approval of the current product is expected to accelerate the approval process for additional products, enhancing the company's product portfolio in the medical aesthetics market [12].

Macro Commentary - The core objective of China's "14th Five-Year Plan" (2026-2030) emphasizes high-quality development, shifting focus from GDP growth to technological self-reliance and economic transformation [2][4] - Key strategic industries highlighted include artificial intelligence, semiconductors, advanced robotics, green energy, aerospace, and industrial software [2] - The plan aims to rebalance the economy towards consumption-driven growth, with increased investment in social services such as healthcare and elder care, benefiting sectors like consumer staples and healthcare [2][4] Market Performance - The Hang Seng Index closed at 25,968, up 0.72% year-to-date performance is 29.45% [2] - The Shanghai Composite Index closed at 3,922, with a year-to-date increase of 17.03% [2] - U.S. markets showed positive performance, with the Dow Jones up 0.27% and the S&P 500 up 0.49% [2][4] Company Analysis - **Giant Bio (2367 HK)**: The approval of its first injectable aesthetic product marks the beginning of a new growth phase for the company. The product is aimed at facial dermal filling to correct dynamic wrinkles [5][6] - The company has a strong channel advantage due to its established network and brand recognition in the aesthetic market, which is expected to drive growth [5] - **Thermo Fisher (TMO US)**: Reported a strong 3Q25 performance with a revenue increase of 5.0% year-on-year and an adjusted EPS growth of 9.7%. The company raised its full-year guidance based on robust performance [6][7] - The demand from pharma and biotech clients is showing positive signs, with revenue growth driven by bioproduction and analytical instruments [7][8] - The company is expected to benefit from the trend of pharmaceutical companies establishing manufacturing facilities in the U.S., which will reflect in its performance by 2027-2028 [9]

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 85.00 [1][10]. Core Insights - The company has received approval for its recombinant type I α1 collagen freeze-dried fiber, marking it as China's first recombinant type I natural sequence collagen facial injection product, primarily used for dermal filling to correct dynamic wrinkles [1][6]. - The product is expected to potentially achieve sales exceeding RMB 1 billion in the medium to long term, with a favorable profit margin [6][10]. - The company is actively tracking its product strategy and market promotion pace, despite short-term stock price fluctuations due to market concerns regarding its cosmetic business performance [6][10]. Financial Projections - Revenue projections for the company are as follows: - 2024: RMB 5,539 million (+57.17%) - 2025E: RMB 7,115 million (+28.45%) - 2026E: RMB 8,777 million (+23.37%) - 2027E: RMB 10,461 million (+19.18%) [5][19]. - Net profit attributable to the parent company is projected to be: - 2024: RMB 2,062 million (+42.06%) - 2025E: RMB 2,600 million (+26.07%) - 2026E: RMB 3,203 million (+23.18%) - 2027E: RMB 3,812 million (+19.03%) [5][19]. Market Position and Competitive Landscape - The company is positioned in a market with few leading players in injectable recombinant collagen, with competitors like Jinjibo focusing on recombinant type III humanized collagen products [7][10]. - The company’s product pipeline includes a recombinant collagen implant product that has been accepted for review, indicating potential for further expansion in the recombinant collagen medical device market [8][10]. Brand Performance - The company's brands, Kefu Mei and Keli Jin, have shown recovery in Q3 2025, with online GMV reaching RMB 615 million and RMB 72 million respectively, reflecting year-on-year growth of 20% and 17% [9][10]. - The company has also expanded its international presence, entering 13 Watsons stores in Singapore with multiple product lines [9][10].

Core Viewpoint - The Hong Kong innovative drug concept stocks have shown strong performance, with several companies experiencing significant gains in their stock prices [1] Group 1: Stock Performance - WuXi AppTec (药明合联) increased by 6% [1] - WuXi Biologics (药明生物) and 3SBio (三生制药) both rose by over 3% [1] - Other companies such as Innovent Biologics (信达生物), Genscript Biotech (巨子生物), and Hengrui Medicine (恒瑞医药) saw increases of over 2% [1]

Market Overview - The Hang Seng Index opened lower but closed up by 186 points, reaching 25,967 points, a 0.72% increase, after fluctuating throughout the day due to news of US-China trade talks in Malaysia [3][4] - The total market turnover was HKD 245.256 billion, with a net inflow of HKD 5.343 billion from northbound trading [3] Advertising Industry - Hong Kong's overall advertising expenditure in Q3 was HKD 8.58 billion, a year-on-year decrease of 5%. Key sectors like banking, healthcare, and beverages showed positive growth, supporting a recovery in advertising spending [7] - In September, advertising spending increased by 5% year-on-year, attributed to improved economic activity and proactive marketing strategies ahead of the fourth quarter [7] Inflation Data - The overall consumer price index in Hong Kong rose by 1.1% year-on-year in September, consistent with August's increase and in line with market expectations. The core inflation rate was slightly lower at 1% [8] AI Adoption in Enterprises - A survey revealed that 88% of employees in surveyed companies use AI tools in their daily work, primarily for customer service, data analysis, and marketing. Over 92% of companies plan to gradually integrate AI into their workflows [9] Corporate News - Ye's Chemical Group acquired approximately 60% of Beijing Xinnuo Haibo Petrochemical Technology for an initial consideration of RMB 288 million (approximately HKD 317 million), with potential adjustments based on profit guarantees [12] - Hongyang Services announced that a major shareholder's pledged shares were subject to forced execution, affecting 72.77% of the company's share capital, but the company's operations remain normal [13] - Juzi Biotechnology received a medical device registration certificate for its collagen injection product, marking a significant advancement in its product offerings [14] - Giordano reported a 1.43% year-on-year decline in Q3 sales, totaling HKD 894 million, while total revenue for the first three quarters increased by 0.64% [15]

Investment Rating - The report maintains a "Buy" rating with a target price of HKD 58.35, down from a previous target of HKD 71.30, indicating a potential upside of 41.6% from the current price of HKD 41.20 [2][4]. Core Insights - The approval of the first injectable aesthetic product, recombinant type I α1 collagen, marks the beginning of a second growth curve for the company, expanding its product matrix in the aesthetic medicine sector [1][8]. - The Chinese aesthetic injection market is projected to reach RMB 147 billion by 2027, with the collagen injection segment expected to grow to RMB 16.8 billion, highlighting significant growth potential [8]. - The company has a strong channel advantage due to its established network and brand recognition in the aesthetic medicine market, which is expected to drive growth from the new injectable products [8]. Financial Summary - Sales revenue is projected to grow from RMB 3,524 million in FY23A to RMB 8,715 million in FY27E, with a CAGR of approximately 17.7% [3][13]. - Net profit is expected to increase from RMB 1,451.8 million in FY23A to RMB 2,820.5 million in FY27E, reflecting a growth rate of 13.5% [3][13]. - The company’s net debt ratio is projected to increase from (57.2%) in FY23A to (73.4%) in FY27E, indicating a shift towards higher leverage [3][13]. Product Development - The company has two additional injectable collagen products in the approval stage, which are expected to enhance its aesthetic product portfolio and address various anti-aging needs [8][9]. - The newly approved injectable product is designed for facial dermal filling to correct dynamic wrinkles, positioning the company competitively in the market [9]. Market Position - The company has established a comprehensive product matrix that includes injectable products, post-surgery recovery dressings, and functional skincare, allowing it to capture a broader market share [1][8]. - The competitive landscape includes several other approved products, but the company’s strong distribution channels and brand recognition are expected to provide a competitive edge [8][9].

Summary of Giant Biogene Holding (2367.HK) Conference Call Company Overview - **Company**: Giant Biogene Holding (2367.HK) - **Industry**: Medical Aesthetics (MA) Key Points and Arguments Product Approval and Market Potential - Giant Biogene received a Medical Device Registration Certificate from the China National Medical Products Administration (NMPA) for its MA product, "Recombinant Type I α1 Subtype Collagen Freeze-dried Fibers" on October 23, 2025, intended for facial dermal tissue filling to correct dynamic wrinkles [1][2] - The approval is expected to provide a long-term upside opportunity, with potential sales exceeding RMB 1 billion and net income between RMB 500-600 million for the MA business [2][7] - The injectable recombinant collagen market is identified as a "blue ocean" with only three approved products currently, indicating significant growth potential [5] Market Dynamics and Competitive Landscape - The skin rejuvenation market is primarily dominated by hyaluronic acid and botulinum toxin, with collagen-based products accounting for only 9% of the market in 2021. This segment is projected to grow at a 24% CAGR from 2021 to 2027, reaching a market size of RMB 14 billion [5] - Giant Biogene's product is the first approved out of four Class III medical aesthetics products in its pipeline, with commercialization preparations actively ongoing, including recruitment for a specialized sales/marketing team [5][9] Financial Projections and Valuation - The product is expected to take 1-2 years to contribute significantly to earnings, with a potential to achieve RMB 1 billion+ in sales and RMB 500-600 million+ in net income, assuming a net profit margin of 50-60% [7] - A 20x P/E ratio is suggested for valuation, indicating a potential incremental valuation upside of RMB 10-12 billion for Giant Biogene in the long run [7] Risks and Concerns - Investors are concerned about the lagging run rate of the Double 11 sales event compared to the 30%+ year-on-year online growth target for the second half of 2025. Day 1 livestreaming on Tmall showed a 40% year-on-year decline [14] - The company is closely monitoring GMV recovery, particularly through key KOLs on Douyin, which has shown acceleration recently [14] Financial Metrics and Market Position - As of October 22, 2025, Giant Biogene's market cap is HKD 38.62 billion, with a projected revenue of RMB 5.54 billion for 2025 and an EBITDA margin of 23% [18] - The company has a price target of HKD 71, representing a potential upside of 72.3% from the current price of HKD 41.20 [18] Product Pipeline - The product pipeline includes several Class III medical aesthetics products, with expected approvals for additional products in 2025 [9][12] Additional Important Information - The approval of the MA product enhances Giant's capability in MA offerings and improves visibility for upcoming products [12] - The company is expected to obtain another license approval by year-end, which could further bolster its market position [13] This summary encapsulates the critical insights from the conference call regarding Giant Biogene Holding's recent developments, market potential, financial projections, and associated risks.